CJC-1295 With DAC vs Sermorelin: Research Comparison

A Side-By-Side Research Comparison Of CJC-1295 With DAC And Sermorelin - a long-acting versus a short-acting GHRH analog. This Reference Compares Mechanism, Evidence Tier, Molecular Identity, And Pharmacokinetics For Qualified Researchers. For In Vitro Laboratory Research Use Only. Not Medical Advice Or Dosing Guidance.

Side-By-Side Comparison

CJC-1295 With DAC versus Sermorelin research comparison
	CJC-1295 With DAC	Sermorelin
Category	Muscle Growth & Performance	Muscle Growth & Performance
Compound Class	Long-acting synthetic GHRH analog with Drug Affinity Complex (DAC) albumin-binding moiety	Synthetic 29-amino acid fragment of endogenous GHRH (GHRH 1-29-NH2)
Evidence Tier	Research Compound	Approved Drug
Molecular Target	GHRH receptor (GHRHR) on pituitary somatotrophs; sustained GH and IGF-1 elevation	GHRH receptor (GHRHR) on anterior pituitary somatotrophs; stimulates endogenous GH gene expression and release
Molecular Weight	3647.1 Da	3357.93 Da
Amino Acid Sequence	tetrasubstituted GRF(1-29) + DAC	GHRH(1-29) amide
CAS Number	446262-90-4	86168-78-7
Half-Life	~6-8 days (albumin-bound, DAC)	~10-20 min
Studied For	GH pulsatile release research, GH-axis anti-aging, Growth hormone deficiency, Extended GH secretion	Pituitary GH-reserve diagnostic, Pediatric GH deficiency (historical), Adult GH-axis / anti-aging research, GH secretagogue research

Open CJC-1295 With DAC And Sermorelin In The Interactive Comparison Tool

About CJC-1295 With DAC

A long-acting growth-hormone-releasing peptide; banned in sport.

Read The Full CJC-1295 With DAC Monograph

About Sermorelin

A growth-hormone-releasing hormone analog formerly approved for childhood GH deficiency; banned in sport.

Read The Full Sermorelin Monograph

Key Differences

Evidence tier differs: CJC-1295 With DAC is classified as Research Compound; Sermorelin is classified as Approved Drug.
Reported half-life differs: CJC-1295 With DAC at ~6-8 days (albumin-bound, DAC) versus Sermorelin at ~10-20 min.
Primary molecular target differs: CJC-1295 With DAC acts on GHRH receptor (GHRHR) on pituitary somatotrophs; sustained GH and IGF-1 elevation; Sermorelin acts on GHRH receptor (GHRHR) on anterior pituitary somatotrophs; stimulates endogenous GH gene expression and release.

Continue Researching

CJC-1295 With DAC · Sermorelin · Compare Tool · Research Library

This Comparison Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption, Diagnosis, Or Treatment. See The Full Research Disclaimer.